Pharmacoeconomics of bisphosphonates for skeletal-related event prevention in metastatic non-breast solid tumours

PharmacoEconomics

Volumn 30, Issue 5, 2012, Pages 373-386

  Carter, John A ^a   Joshi, Avani D ^b   Kaura, Satyin ^c   Botteman, Marc F ^a  

^a PHARMERIT INTERNATIONAL   (United States)

^b ABBOTT LABORATORIES   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Bisphosphonates; Bone metastases; Cost effectiveness; Solid tumours; Zoledronic acid

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; PLACEBO; ZOLEDRONIC ACID;

BONE DISEASE; BONE METASTASIS; CANCER SURVIVAL; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG DOSE REDUCTION; DRUG TOLERABILITY; FRANCE; GERMANY; HEALTH CARE UTILIZATION; HUMAN; HYPERCALCEMIA; KIDNEY CARCINOMA; LUNG CANCER; NETHERLANDS; ORTHOPEDIC SURGERY; PATHOLOGIC FRACTURE; PORTUGAL; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SOLID TUMOR; SPINAL CORD COMPRESSION; TREATMENT DURATION; UNITED KINGDOM;

BONE DENSITY CONSERVATION AGENTS; BONE DISEASES; BONE NEOPLASMS; CARCINOMA, RENAL CELL; COST-BENEFIT ANALYSIS; DIPHOSPHONATES; DRUG COSTS; EUROPE; HEALTH CARE COSTS; HUMANS; IMIDAZOLES; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MALE; NEOPLASMS; PROSTATIC NEOPLASMS;

EID: 84859803733     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11631390-000000000-00000     Document Type: Review

References (56)

1. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001; 27 (3): 165-76
2. Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role ofbisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003; 21 (21): 4042-57
3. Lipton A. Management of bone metastases in breast cancer. Curr Treat Options Oncol 2005; 6 (2): 161-71
4. Coleman RE. Bisphosphonates: clinical experience. Oncologist 2004; 9 Suppl. 4: 14-27
5. Nagy Z. Zoledronic acid (ZOMETA): a significant improvement in the bone metastases. Pathol Oncol Res 2005; 11 (3): 186-7
6. Smith MR. Zoledronic acid to prevent skeletal complications in cancer: corroborating the evidence. Cancer Treat Rev 2005; 31 Suppl. 3: 19-25
7. Ross JR, Saunders Y, Edmonds PM, et al. A systematic review of the role of bisphosphonates in metastatic disease. Health Technol Assess 2004; 8 (4): 1-176
8. Coleman RE. Bisphosphonates in breast cancer. Ann Oncol 2005; 16 (5): 687-95
9. Pavlakis N, Schmidt R, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev 2005; 3: CD003474
10. Yuen KK, Shelley M, Sze WM, et al. Bisphosphonates for advanced prostate cancer. Cochrane Database Syst Rev 2006; 4: CD006250
11. Small EJ, Smith MR, Seaman JJ, et al. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol 2003; 21 (23): 4277-84
12. Lipton A. Treatment of bone metastases and bone pain with bisphosphonates. Support Cancer Ther 2007; 4 (2): 92-100
13. Botteman M. Cost-effective formularies for the management of bone metastases secondary to breast cancer. Hospital Pharm Eur 2007 Jul/Aug [online]. Available from URL: http://www.hospitalpharmacyeurope.com/default. asp?title=Cost-effective-formularies-for-the-management -of-bone-metastases- secondary-to-breast-cancer&page= article.display&article.id=4700 [Accessed 2010 Aug 1]
14. McKeage K, Plosker GL. Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases. Pharmacoeconomics 2008; 26 (3): 251-68
15. Carter JA, Joshi A, Kaura S, et al. Cost effectiveness of zoledronic acid in the management of skeletal metastases in hormone-refractory prostate cancer patients in France, Germany, Portugal, and the Netherlands. J Med Econ 2011; 14 (3): 288-98
16. Reed SD, Radeva JI, Glendenning GA, et al. Costeffectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer. J Urol 2004; 171 (4): 1537-42
17. Joshi AD, Carter JA, Botteman MF, et al. Cost-effectiveness of zoledronic acid in the management of skeletal metastases in patients with lung cancer in France, Germany, Portugal, the Netherlands, and the United Kingdom. Clin Ther 2011; 33 (3): 291-304
18. Botteman MF, Meijboom M, Foley I, et al. Cost-effectiveness of zoledronic acid in the prevention of skeletal-related events in patients with bone metastases secondary to advanced renal cell carcinoma: application to France, Germany, and the United Kingdom. Eur J Health Econ 2011; 12 (6): 575-88
19. Saad F, Gleason DM, Murray R, et al. A randomized, placebo- controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94 (19): 1458-68
20. Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial - the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003; 21 (16): 3150-7
21. Lipton A, Zheng M, Seaman J. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer 2003; 98 (5): 962-9
22. DesHarnais CL, Bajwa K, Markle JP, et al. A microcosting analysis of zoledronic acid and pamidronate therapy in patients with metastatic bone disease. Support Care Cancer 2001; 9 (7): 545-51
23. Cella D, Li JZ, Cappelleri JC, et al. Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial. J Clin Oncol 2008; 26 (22): 3763-9
24. De Wit GA, Busschbach JJ, De Charro FT. Sensitivity and perspective in the valuation of health status: whose values count? Health Econ 2000; 9 (2): 109-26
25. Gold MR. Cost-effectiveness in health and medicine. New York (NY): Oxford University Press, 1996
26. McDonough CM, Tosteson AN. Measuring preferences for cost-utility analysis: how choice of method may influence decision-making. Pharmacoeconomics 2007; 25 (2): 93-106
27. Krahn M, Ritvo P, Irvine J, et al. Patient and community preferences for outcomes in prostate cancer: implications for clinical policy. Med Care 2003; 41 (1): 153-64
28. Gabriel SE, Kneeland TS,Melton III LJ, et al. Health-related quality of life in economic evaluations for osteoporosis: whose values should we use?Med DecisMaking 1999; 19 (2): 141-8
29. Aapro M, Abrahamsson PA, Body JJ, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 2008; 19 (3): 420-32
30. Dearnaley DP, Sydes MR, Mason MD, et al. A doubleblind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). J Natl Cancer Inst 2003; 95 (17): 1300-11
31. Jacobson MW. Cost effectiveness of coronary bypass surgery versus angioplasty. N Engl J Med 1997; 336 (25): 1840-1
32. Trippoli S, Vaiani M, Messori A, et al. Survival gain in costeffectiveness studies [letter]. J Clin Oncol 2000; 18 (18): 3318
33. Trippoli S, Messori A. Cost effectiveness of sunitinib. J Clin Oncol 2008; 26 (35): 5829-30
34. Hillner BE. Survival gain in cost-effectiveness studies - response [letter]. J Clin Oncol 2000; 18 (18): 3318
35. Hlatky MA, Rogers WJ, Johnstone I, et al. Medical care costs and quality of life after randomization to coronary angioplasty or coronary bypass surgery. Bypass Angioplasty Revascularization Investigation (BARI) Investigators. N Engl J Med 1997; 336 (2): 92-9
36. DePuy V, Anstrom KJ, Castel LD, et al. Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer. Support Care Cancer 2007; 15 (7): 869-76
37. Henk HJ, Kaura S. Assessment of zoledronic acid treatment patterns and clinical outcomes in patients with bone metastases from genitourinary cancers. J Med Econ 2012; 15 (1): 185-94
38. Henk HJ, Kaura S, Teitelbaum A. Retrospective evaluation of the clinical benefit of long-term continuous use of zoledronic acid in patients with lung cancer and bone metastases. J Med Econ 2012; 15 (1): 195-204
39. Coleman RE, Marshall H, Cameron D, et al. Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med 2011; 365 (15): 1396-405
40. Hillner BE, Weeks JC, Desch CE, et al. Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol 2000; 18 (1): 72-9
41. McKean H, Miller RC, Jatoi A. Non-traumatic vertebral fractures in patients with locally advanced esophageal cancer: a previously unreported, unrecognized problem. Dis Esophagus 2007; 20 (2): 102-6
42. Ross PD, Davis JW, Epstein RS, et al. Pain and disability associated with new vertebral fractures and other spinal conditions. J Clin Epidemiol 1994; 47 (3): 231-9
43. Costa L, Lipton A, Coleman RE. Role of bisphosphonates for the management of skeletal complications and bone pain from skeletal metastases. Support Cancer Ther 2006; 3 (3): 143-53
44. Dranitsaris G, Hsu T. Cost utility analysis of prophylactic pamidronate for the prevention of skeletal related events in patients with advanced breast cancer. Support Care Cancer 1999; 7 (4): 271-9
45. Weinfurt KP, Li Y, Castel LD, et al. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 2005; 16 (4): 579-84
46. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011; 377 (9768): 813-22
47. Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011; 29 (9): 1125-32
48. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010; 28 (35): 5132-9
49. Drug topics red book. Montvale (NJ): Thomson Healthcare, 2011
50. Aapro MS. Denosumab for bone metastases from breast cancer: a new therapy option? J Clin Oncol 2011; 29 (14): e419-29
51. Aragon-Ching JB. Unravelling the role of denosumab in prostate cancer. Lancet 2011; 377 (9768): 785-6
52. Fornier MN. Denosumab: second chapter in controlling bone metastases or a new book? J Clin Oncol 2010; 28 (35): 5127-31
53. West H. Denosumab for prevention of skeletal-related events in patients with bone metastases from solid tumors: incremental benefit, debatable value. J Clin Oncol 2011; 29 (9): 1095-8
54. Carter JA, Snedecor SJ, Kaura S, et al. Cost-effectiveness of zoledronic acid (ZOL) versus denosumab (Dmab) in prevention of skeletal-related events (SREs) in metastatic breast cancer (mBC). In: American Society of Clinical Oncology Annual Meeting; 2011 Jun 3-7; Chicago (IL). J Clin Oncol; Suppl. 29: a9025
55. Snedecor SJ, Carter JA, Kaura S, et al. Cost-effectiveness of zoledronic acid (ZOL) versus denosumab (Dmab) in prevention of skeletal-related events (SREs) in castrationresistant prostate cancer metastatic to the bone (mCRPC). In: American Society of Clinical Oncology Annual Meeting; 2011 Jun 3-7; Chicago (IL). J Clin Oncol; Suppl. 29: a4581
56. Xie J, Namjoshi M, Wu EQ, et al. Economic evaluation of denosumab compared with zoledronic acid in hormonerefractory prostate cancer patients with bone metastases. J Manag Care Pharm 2011; 17 (8): 621-43